Quarterly report pursuant to Section 13 or 15(d)

Organization, Plan of Business Operations (Details)

v3.20.2
Organization, Plan of Business Operations (Details) - USD ($)
$ / shares in Units, $ in Thousands
Feb. 08, 2019
Sep. 30, 2020
Dec. 31, 2019
Nov. 12, 2018
Cash and cash equivalents   $ 4,325 $ 8,745  
Accumulated deficit   $ (72,275) $ (68,117)  
Line of Credit [Member]        
Interim Financing Amount $ 7,000      
Invagen Pharmaceuticals Inc [Member]        
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned $ 31,500     $ 215,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 5,833,333      
Business Acquisition, Share Price $ 6.00      
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 33.30%      
Invagen Pharmaceuticals Inc [Member] | Common Shares        
Stock Issued During Period, Value, Acquisitions $ 180,000